Canopy Growth Stock Lagged the TSX by 5.7% in March

Canopy Growth stock price underperformed the TSX Index in March as investors have low risk tolerance and are looking for safety.

| More on:
edit Jars of marijuana

Image source: Getty Images

Canopy Growth (TSX:WEED)(NYSE:CGC) stock price was already in the throes of despair before the coronavirus crisis. The stock had already fallen dramatically from late 2018/early 2019 highs as the cannabis bubble burst. In March, Canopy Growth stock price continued to underperform the TSX, lagging it by 5.7%.

During the month of March, all eyes were on developments related to the coronavirus. Societies have been attempting to lessen the human toll of this virus. They are doing this by taking measures that were unimaginable only a few months ago.

As the realities of social distancing and isolation became increasingly clear, the economic fallout also became crystal clear. Hence, the TSX fell sharply, just as all global markets did.

Canopy Growth stock price lags the TSX as its stores are deemed “non-essential” businesses in some provinces

Some provinces, most notably Ontario, have closed cannabis stores in March. While online orders can still be placed, this places a damper on the industry. But even this has been lacking clarity and predictability.

This decision was a reversal of a prior decision that listed cannabis stores as essential, so it’s has been a very fluid situation — and more uncertainty in an already uncertain environment.

Canopy Growth stock price lags the TSX as the risk outweighs the potential in investors’ minds

It goes without saying that the risk tolerance of investors has fallen dramatically lower in recent months. The coronavirus crisis gave the cannabis industry another push down the slippery slope.

But Canopy Growth supplies cannabis for the medical and recreational marijuana markets. As such, it may not be as risky as investors may be thinking, at least on the surface, as revenue and demand should prove to be highly resilient.

This spending should prove to be insensitive to the economy in much the same way as alcoholic beverages are. Also, the crisis may very well increase demand for CBD medicinal products. Health products such as CBD-based products have surely increased value in this environment.

Yet, logistical and regulatory problems are barriers to the functioning of this industry. We have seen the bubble bursting as cannabis companies dealt with many issues in this new industry.

From government missteps to company missteps and even fraud, cannabis stocks have been fraught with uncertainty and risk. Canopy Growth stock price has fallen 72.5% from its highs.

And the risk doesn’t end there. The company’s balance sheet is in bad shape as it continues to report big losses. Thus, it’s clear that the company is not in any state to withstand a crisis.

Foolish bottom line

On the bright side, demand for cannabis and cannabis products is theoretically quite inelastic, which means that economic troubles should not affect sales of these products. In fact, for many, cannabis products are as essential to them as traditional prescription medicine.

The medical marijuana market will whether this storm easily. The recreational marijuana market will likely see a boost in demand.

In summary, the reasons for the underperformance of Canopy Growth stock price seems quite simple. The outlook is proving to be more complicated, as competing forces are at work.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »